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Abstract
Background: The growth and metastasis of tumors depend on the development of an adequate blood
supply via angiogenesis. Recent studies indicate that the inducible nitric oxide synthase (iNOS), vascular
endothelial growth factor (VEGF) and the tumor suppressor p53 are fundamental play-markers of the
angiogenic process. Overexpression of iNOS and VEGF has been shown to induce angiogenesis in
tumors. P53 suppresses angiogenesis by down-regulating VEGF and iNOS. The correlation of
expression of p53, VEGF and iNOS and clinical features in gastric carcinogenesis, however, has not
been well characterized.
Methods: The expression of p53, iNOS and VEGF in gastric precancerous and cancerous lesions and
its relation with the clinical features was determined with immunohistochemistry (avidin-biotin-
peroxidase complex method) on 55 randomly selected GC patients and 60 symptom-free subjects
from the mass survey in the high-incidence area for GC in Henan, northern China.
Results: The positive immunostainig rates for p53, iNOS and VEGF in gastric carcinomas were 51%,
44% and 51%, respectively, and correlated well with TNM stages, but did not show significant
difference among the groups with different degrees of gastric wall invasion depth by GC. A positive
immunostaining reaction for the iNOS protein was significantly correlated with lymph node metastasis
(p = 0.019; Spearman correlation coefficient). P53 protein accumulation was higher in the poorly-
differentiated gastric carcinoma than in well-differentiated one. In gastric biopsies, no positive
immunosatining was observed for p53, iNOS and VEGF in the histologically normal tissue and chronic
superficial gastritis (CSG). However, p53, iNOS and VEGF positive immunostaining was observed in
the tissues with different severities of lesions of chronic atrophic gastritis (CAG), intestinal metaplasia
(IM) and dysplasia (DYS), and the positive rates increased with the lesion progression from CAG to
IM to DYS. A high coincidental positive and negative immunostaining rate for p53, iNOS and VEGF was
observed both in biopsy samples with CAG, IM and DYS from the symptom-free subjects and in gastric
cancer tissue from the GC patients.
Conclusions: The present results indicated that p53 protein accumulation and increased expression
of iNOS and VEGF might be responsible for gastric carcinogenesis and tumor aggressiveness of gastric
cancer.
Published: 29 April 2002
BMC Cancer 2002, 2:8
Received: 6 November 2001
Accepted: 29 April 2002
This article is available from: http://www.biomedcentral.com/1471-2407/2/8
© 2002 Feng et al; licensee BioMed Central Ltd. Verbatim copying and redistribution of this article are permitted in any medium for any purpose, provided 
this notice is preserved along with the article's original URL.BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/8
Page 2 of 7
(page number not for citation purposes)
Gastric adenocarcinoma (GC) is one of the most common
malignant diseases in China. Although the GC has been
declined in its mortality rate, it remains the leading cause
of cancer-related deaths in this country (Parkin et al.,
1992; World Health Organization, 1994; Nomura A,
1996). Gastric carcinogenesis is considered as a multistage
progressive process. The early indicator for the subject pre-
disposed to GC is abnormal hyperproliferation of gastric
epithelial cells, such as chronic atrophic gastritis (CAG),
DYS and intestinal metaplasia (IM), which have been con-
sidered as precancerous lesions of GC (You et al., 1993;
Correa P, 1992). However, the information for the mech-
anism of gastric carcinogenesis is very limited.
The growth and metastasis of tumors depend on the de-
velopment of an adequate blood supply via angiogenesis.
Recent studies indicate that the inducible nitric oxide syn-
thase (iNOS), vascular endothelial growth factor (VEGF)
and tumor suppressor p53 are fundamental play-makers
of the angiogenic process (Ambs et al., 1994; Jekins et al.,
1995; Forrester et al., 1996; Chiarugi et al., 1998). iNOS is
one of the isoforms of nitric oxide synthase that catalyzes
the formation of nitric oxide, a regulator of vascular per-
meability. VEGF is a dimeric glycoprotein and has specific
mitogenic activity for endothelial cells. Over-expression
of iNOS and VEGF could induce angiogenesis in tumors.
P53 suppresses angiogenesis by down-regulating VEGF
and iNOS. Mutant p53 potentiates protein kinase C in-
duction of VEGF expression (Zhang et al., 2000). In a tu-
morigenicity model using human fibroblast cells, the loss
of wild-type p53 and transfection of activated ras led to in-
creased VEGF expression (Devavrata et al., 1995). Tran-
sient transfection of wild-type p53 and of v-src has been
found to exert opposing effects on human VEGF gene pro-
moter activity in human glioblastoma and transformed
human fetal kidney cells (Devavrata et al.,1995). Howev-
er, because wild-type p53 did not repress hypoxia-induced
transcription of the VEGF gene in stably transfected hu-
man colorectal carcinoma and human hepatoblastoma
cells with an inducible p53-estrogen-receptor fusion pro-
tein expression system (Ambs et al., 1998), it has been
proposed that there is a need for caution in interpreting
p53 function on the basis of cells transiently overexpress-
ing this protein. Nevertheless, mutant p53 has been corre-
lated with increased VEGF expression in human lung
cancer (Ambs et al., 1994), and colorectal cancer (Ambs et
al.,1999) by immunohistochemical staining of surgical
specimens. It has been reported that dysfunction of the
p53/MDM-2 pathway can be found in more than two-
thirds of angiosarcomas; thus, mutant p53 influences the
development of angiosarcoma not only by affecting
growth and apoptosis control but also by up-regulating
VEGF (Chinrugi et al., 1998). We hypothesized that alter-
ations of p53, iNOS and VEGF expression may contribute
to gastric carcinogenesis and influence the clinical behav-
ior of GC via angiogenesis. The correlation of expression
of p53, VEGF and iNOS and clinical features in gastric car-
cinogenesis, however, has not been well characterized.
To characterize the changes of p53, iNOS and VEGF ex-
pression in human gastric carcinogenesis, the present
study was undertaken to determine the protein level of
p53, iNOS and VEGF in normal tissues and the tissues
with different severities of lesions of CSG, CAG, DYS, IM
and GC with and without lymph node metastasis from
surgically resected human GC and gastric biopsies from
symptom-free subjects. The subjects were from Linzhou
and nearby county Huixian in Henan province, the high-
incidence area for GC in northern China.
Materials and Methods
Patients
The present investigation included 55 randomly selected
GC patients and 60 symptom-free subjects from the mass
survey in the high-incidence area for GC. Fifty-five GC pa-
tients were performed gastric cancer surgery at the
Linzhou People's Hospital (n = 26) and The Second Affil-
iated Hospital of Henan Medical University (n = 29) from
1996 to 1998. Before surgery, none of the patients re-
ceived any kinds of chemical or radiation therapy. The
median age of the patients was 61 years (30 ~ 77 years).
Cancer specimens were classified based on TNM as stage
T1 (19 patients, 35%), T2 (14 patients, 25%), T3 (12 pa-
tients, 22 %) and T4 (10 patients, 18%). The tumors were
histologically graded as well-differentiated (15 patients,
27%), moderate-differentiated (14 patients, 25%) and
poorly-differentiated (26 patients, 47%). Of the 55 pa-
tients, 35 occurred local lymph node metastasis (64%).
Gastric biopsies were taken from 60 symptom-free sub-
jects who volunteered to participate in a routine endo-
scopic screening for esophageal and gastric cancer in
Huixian, China. No selection process was involved. Of the
60 subjects examined, there were 35 males and 25 fe-
males. The median age of the subjects was 59 years (28 ~
70 years). The biopsies were taken each from the pylorus
of the stomach from each subject.
Tissue processing
All the surgically resected specimens and biopsy samples
were fixed with 10% neutral formalin, embedded with
paraffin, and serially sectioned at 5 µm. The sections were
mounted onto the histostick-coated slides. Four or five ad-
jacent ribbons were collected for histopathological analy-
sis (hematoxylin and eosin stain) and for
immunohistochemical staining.
Histopathological Analysis
Histopathological diagnosis for gastric epithelia was
made according to cellular morphological changes and
tissue architecture using previously established criteriaBMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/8
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(Wang, et al., 1994; You, et al., 1993). In brief, CSG: an in-
flammation manifested by mild lymphocyte and plasma-
cell infiltration; CAG: glandular morphology disappeared
partially or completely absent in the mucosa and replaced
by connective tissue, inter-glandular space was infiltrated
mainly by plasma cells and lymphocytes; DYS: character-
ized by nuclear atypia with or without architectural ab-
normalities in the gastric epithelium, but without
invasion; IM: confirmed by the presence of goblet cells in
gastric mucosa; adenocarcinoma (AC): invasion of neo-
plastic gastric cells through the basement membrane.
Immunohistochemical staining
Anti-p53 antibody is a monoclonal mouse anti-serum
against p53 of human origin, and recognizes both wild-
type and mutant p53 (Ab-6, Oncogene Science, Manhas-
set, NY). Anti-iNOS antibody is a monoclonal mouse
anti-serum against the C-terminal domain of iNOS of hu-
man origin (sc-7271, Santa Cruz Biotechnology, Inc., San-
ta Cruz, CA). Anti-VEGF antibody is a polyclonal rabbit
anti-serum against VEGF of human origin and recognizes
an amino-terminal epitope found in VEGF121, 165, 189 and
206 (Ab-2, Oncogene Science, Manhasset, NY). The avi-
din-biotin-peroxidase complex method was used for the
immunostaining of p53, iNOS and VEGF. In brief, after
dewaxing, inactivating endogenous peroxidase activity
and blocking cross-reactivity with normal serum
(Vectastain Elite Kit; Vector, Burlingame, CA), the sections
were incubated overnight at 4C with a diluted solution of
the primary antibodies (1:1000 for p53, 1:200 for iNOS
and 1:100 for VEGF). Location of the primary antibodies
was achieved by subsequent application of a biotinylated
anti-primary antibody, an avidin-biotin complex conju-
gated to horseradish peroxidase, and diaminobenzidine
(Vectastain Elite Kit, Vector, Burlingame, CA). The slides
were counter-stained by hematoxylin. Negative controls
were established by replacing the primary antibody with
PBS and normal mouse or rabbit serum. Known immu-
nostaining-positive slides were used as positive controls.
Specific staining for each protein was categorized as either
positive or negative based on the presence of brown-color
staining. More than 10% cells positively stained were
graded as positive. Clear staining for nuclei (p53), cyto-
plasm and cell membrane (VEGF and iNOS) was the cri-
terion for a positive reaction (Wang et al.,1994). All the
immunostaining slides were observed by two pathologists
(L D Wang and L H Jiao). The slides with different diagno-
sis by two pathologists were read again (less than 5%), un-
til the agreed diagnosis was made.
Statistical Analysis
The X2 test was used for the percentage of samples with
positive stain. Spearman correlation test and linear ten-
dency test were used for the correlation between positive
rates and different severities of lesions (p < 0.05 was con-
sidered significant).
Results
Histopathologically, all the 55 surgically-resected gastric
specimens were confirmed as adenocarcinoma. Of the 55
GC patients, 11 cases occurred the invasion within sub-
mucosa, 44 with whole-muscle layer. Of the 60 biopsy-
samples examined, 10 were diagnosed as normal, 15 as
CSG, 9 as CAG, 16 as IM with CAG, and 10 as DYS (Table
1).
The positive immunostaining for p53, iNOS and VEGF
was observed in the gastric epithelial cells and cancer cells
with different rates in the lesions of CAG, DYS, IM and
GC. But, the positive immunostaining for p53, iNOS and
VEGF was not observed in normal gastric epithelial tissue
and CSG. Figure 1, 2 and 3 shows the representative of
p53, iNOS and VEGF immunostaining in GC. p53 immu-
noreactivity was located in the nuclei, VEGF and iNOS im-
munoreactivity were located mainly in the cytoplasm and
cell membrane. iNOS immunostaining was confirmed by
Western Blot on part of iNOS positive and negative slides
(three slides for each), and consistent results were ob-
tained for iNOS immunohistochemistry and Western Blot
(data not shown). The positive immunostaining rate for
p53 was very low in CAG, and slightly increased in IM and
DYS, and significantly increased in GC (Table 1). Similar
results were observed in iNOS and VEGF (Table 1). P53
positive immunosatining rate in well-differentiated GC
was lower than that in poorly-differentiated GC (p =
0.012, Table 2). iNOS positive staining was similar among
Figure 1
Immunostaining of p53 in gastric carcinoma. Immunoreactiv-
ity is located in cell nuclei (Arrows). 20XBMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/8
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the GC with different degree of differentiation. Although
VEGF immunostaining rate in poorly-differentiated GC
was higher than in well-differentiated GC, the difference
was not significant (Table 2).
iNOS positive immunostaining rate in the cases with deep
invasion of GC (through muscle layers) was higher than
in those with superficial invasion (within submucosa),
but, the difference was not significant (Table 3). P53 and
VEGF immunostaining was similar in GC patients with
superficial and deep invasion.
iNOS immunosatining rate in the cases with lymph node
metastasis was higher than that in those without lymph
node metastasis (p = 0.014, Table 4). However, there was
no difference observed for p53 and VEGF between the cas-
es with and without lymph node metastasis.
P53 immunostaining rate in the cases with TNM grade T1
was lower than that in those with TNM grade T2, T3 and
T4 (T1:T3, p = 0.023; T1:T4, p = 0.012). Similar results
were observed in VEGF (T1:T2 and T2:T3, p = 0.015;
T1:T4, p = 0.014; T2:T4, p = 0.01, Table 5). However, there
was no difference for iNOS immunostaining between the
cases with different TNM stages.
A higher coincidental expression of p53, iNOS and VEGF
in GC was observed. Of the 55 cases examined, there were
20 cases showing positive staining both for p53 and iNOS
(36%), 23 cases showing negative staining for both p53
and iNOS (42%) (p = 0.005, Table 6), 19 cases showing
positive staining both for p53 and VEGF (35%) and 18
cases showing negative for both p53 and VEGF (33%) (p
= 0.01, Table 7). The correlations were significant.
Figure 2
Immunostaining of iNOS in gastric carcinoma. Immunoreac-
tivity is located mainly in cytoplasm and cell nuclear mem-
brane. 10X
Figure 3
Immunostaining of VEGF in gastric carcinoma. Immunoreac-
tivity is located in cytoplasm and cell membrane. 10X
Table 1: Immunoreactivity of p53, iNOS and VEGF in gastric normal epithelia and the epithelia with different severities of lesions
P53 iNOS VEGF
No. of samples examined No. of positive stain n (%) No. of positive stain n (%) No. of positive stain n (%)
Normala 10 0 (0) 0 (0) 0 (0)
CSGb 15 0 (0) 0 (0) 0 (0)
CAGc 9 1 (11) 0 (0) 2 (22)
IMd 16 3 (19) 2 (13) 5 (31)
DYSe 10 3 (30) 4 (40) 5 (50)
GCf 55 28 (51) 24 (44) 28 (50)
P53: c:f p = 0.02 d::f p = 0.013; iNOS: c:f p = 0.03 d:f p = 0.015; VEGF: c:f p = 0.014 d:f p = 0.015BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/8
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Table 2: Immunoreactivity of iNOS, p53 and VEGF in GC and its correlation with different degrees of differentiation
P53* iNOS VEGF
Differentiation degree of GC No. of samples examined No. of positive stain n (%) No. of positive stain n (%) No. of positive stain n (%)
Well-differentiateda 15 5 (33) 7 (47) 6 (40)
Moderate-differentiatedb 14 6 (43) 5 (36) 6 (43)
Poorly-differentiatedc 26 17 (66) 12 (46) 16 (61)
* a:c p = 0.012
Table 3: Immunoreactivity of p53, iNOS and VEGF and its correlation with invasion depth of gastric carcinoma
P53 iNOS VEGF
Invasion depth of GC No. of samples Examined No. of positive stain n (%) No. of positive stain n (%) No. of positive stain n (%)
Within mucosa 11 5 (46) 3 (27) 6 (55)
Muscle layer 44 23 (52) 21 (48) 22 (50)
Table 4: Immunoreactivity of p53, iNOS and VEGF and its correlation with lymph node metastasis of gastric carcinoma
P53 iNOS* VEGF
Lymph node metastasis No. of samples Examined No. of positive stain n (%) No. of positive stain n (%) No. of positive stain n (%)
Yes 35 18 (51) 19 (55) 21 (60)
No 20 10 (50) 5 (25) 7 (35)
* p = 0.014
Table 5: Immunoreactivity of p53, iNOS and VEGF and its correlation with Clinical TNM classification
P53* iNOS VEGF**
TNM stages No. of samples examined No. of positive stain n (%) No. of positive stain n (%) No. of positive stain n (%)
T1 19 7 (37)a 7 (37) 8 (42)a
T2 14 6 (43)b 4 (29) 4 (29)b
T3 12 8 (67)c 7 (58) 8 (67)c
T4 10 7 (70)d 6 (60) 8 (80)d
*a:c p = 0.023, a:d p = 0.012; **a:b and b:c p = 0.015, a:d p = 0.014, b:d p = 0.01BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/8
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Discussion
An interesting observation in this study was that the im-
munoreactivity of p53, iNOS and VEGF occurred in the
early stage of gastric carcinogenesis. The positive immu-
nostaining cells were invariably associated with cell prolif-
erate activity. With the lesions progressed from normal to
CSG to CAG to IM to DYS, and to GC, the positive immu-
nostaining rates for p53, iNOS and VEGF increased signif-
icantly, the increasing tendency for p53, iNOS and VEGF
had a good linear correlation with lesions progression.
The present results indicated that p53 protein accumula-
tion and increased expression of iNOS and VEGF may be
important molecular events involved in the early stage of
gastric carcinogenesis.
Another interesting observation was that, a high coinci-
dental positive immunostaining rates for p53 and iNOS
(36%) and p53 and VEGF (35%) was observed (Table 6
and 7). This result was consistent with the findings in hu-
man lung and colon carcinomas (Ambs et al., 1999). Al-
though p53 antibody used in this study could not
differentiate wild-type p53 from mutant p53, previous
studies have indicated that p53 protein detected by im-
munohistochemistry seems to representative most mu-
tant p53. Accumulation of p53 is an indicator for a loss of
p53 tumor suppressor function. Both mutations and pro-
tein-protein interactions can cause a p53 accumulation
(Wang, et al., 1994). Considering that p53 protein accu-
mulation was correlated with poorly-differentiation and
T2, T3 and T4 TNM stage of GC, we concluded that p53
protein accumulation in this study may lead to the loss of
cell proliferation control and inhibition for iNOS and
VEGF, possibly because of p53 gene mutation. Thus, the
high coincidental expression of iNOS and VEGF and p53
protein accumulation may be important events to en-
hance gastric carcinogenesis and poorly clinical features
and may be useful biomarkers to assess risk for the devel-
opment of GC. Recent studies on Japanese GC patients
have showed that increased expression of VEGF and p53
protein accumulation are associated with intra-tumoral
angiogenesis (Takeuchi, et al., 2000; Saito, et al., 1999)
and poor prognosis (Skatani, et al., 2000; Ikeguchi, et al.,
2000; Maeda, et al., 1998). Rajnkova reported that in-
creased expression of iNOS may promote gastric cancer
progression by providing a selective growth advantage to
tumor cells with non-functioning p53. (Rajnkova, et al.,
2001)
The third observation in this study was that increased ex-
pression of iNOS and VEGF and p53 protein accumula-
tion occurred with a high frequency in gastric biopsy
samples with IM. IM, which may be defined as the re-
placement of gastric mucosa by glands which have the his-
tological, histochemical, and physiological characteristics
of the small intestine, has been strongly associated with
stomach cancer. The present results demonstrated that IM
was a unstable stage with active molecular changes, and
further analysis to compare these changes with normal
small intestine will provides more information for the sig-
nificance of IM in gastric carcinogenesis.
Finally, the present study demonstrated that the positive
immunostaining rates of iNOS was correlated well with
GC lymph node metastasis, increased expression of VEGF
and p53 protein accumulation was related with TNM stag-
es and GC differentiation. These findings indicate that
p53, iNOS and VEGF may be useful biomarkers for GC ag-
gressiveness. The molecular basis for the observed expres-
sion of iNOS and VEGF and p53 protein accumulation
and their roles in the progression of gastric pre-cancerous
lesions and angeogenesis requires to be carefully investi-
gated in the laboratory and follow-up studies.
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Table 6: Coincidental expression of p53 and iNOS protein in the 
gastric carcinoma
p53 (+) p53 (-)
n (%) n (%)
iNOS (+) 20 (36) 4 (7)
iNOS (-) 8 (15) 23 (42)
X2 = 15.68, p = 0.005
Table 7: Coincidental expression of p53 and VEGF protein in the 
gastric carcinoma
p53 (+) p53 (-)
n (%) n (%)
VEGF(+) 19 (35) 9 (16)
VEGF(-) 9 (16) 18 (33)
X2 = 6.56, p = 0.01BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/8
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